Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Multiple Sclerosis

Free Subscription Articles published in Neurology Retrieve available abstracts of 207 articles: HTML format

Single Articles

October 2026
1. APAP MANGION S, Wade C, Coles D, Burton R, et al
   Developing Interim Outcome Measures for Multi-Arm Multistage Clinical Trials in Multiple Sclerosis.
   Neurology. 2026;107:e218426.
   PubMed     Abstract available
   
   
   
2. GRAVESTEIJN AS, Nauta IM, Stob M, Wilmsen N, et al
   Sustained Benefits of a Multidomain Lifestyle Intervention in Multiple Sclerosis in the LIMS Study: A 24-Month Follow-Up.
   Neurology. 2026;107:e218542.
   PubMed     Abstract available
   
   
   
3. LIAMPAS A, Artemiadis A, Tseriotis VS, Prados F, et al
   Prevalence of Slowly Expanding Lesions in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis.
   Neurology. 2026;107:e218474.
   PubMed     Abstract available
   
   
   September 2026
4. FERNANDEZ V, Pappolla A, Carbonell-Mirabent P, Castillo M, et al
   Refining Treatment Monitoring in Patients With Relapsing Multiple Sclerosis Based on Changes on Neurofilament Light Chain Z-Scores.
   Neurology. 2026;107:e218451.
   PubMed     Abstract available
   
   
   
5. GRANBERG T
   Paramagnetic Rim Lesions and Their Predictive Value of Future Progression in People With Multiple Sclerosis.
   Neurology. 2026;107:e218582.
   PubMed    
   
   
   
6. FURLAN R, Rossi E
   Longitudinal Neurofilament Light Chain Z-Score Dynamics: Bridging the Gap Between Research and Routine Monitoring in Multiple Sclerosis.
   Neurology. 2026;107:e218505.
   PubMed    
   
   
   
7. LAUERER M, Voon CC, McGinnis J, Sepp D, et al
   The Prognostic Value of Paramagnetic Rim Lesions in People With Multiple Sclerosis.
   Neurology. 2026;107:e218428.
   PubMed     Abstract available
   
   
   
8. SOLOMON AJ, Brownlee WJ, Viswanathan S, Fadda G, et al
   Application of the 2024 McDonald Criteria: Earlier Diagnosis and Avoiding Misdiagnosis of Multiple Sclerosis in a Global Setting.
   Neurology. 2026;107:e218425.
   PubMed     Abstract available
   
   
   August 2026
9. BALSHI A, Alves C, Ullrich NJ, Benson LA, et al
   Child Neurology: A Case of Concurrent Neurofibromatosis Type 1 and Multiple Sclerosis by 2024 Criteria.
   Neurology. 2026;107:e218240.
   PubMed     Abstract available
   
   
   
10. SCHOOF L, Heijnen R, Hogenboom L, Van Kempen ZLE, et al
    Value of Annual MRI Monitoring in Patients With Multiple Sclerosis Treated With Ocrelizumab: A Number Needed to Scan Analysis.
    Neurology. 2026;107:e218379.
    PubMed     Abstract available
    
    
    
11. PREZIOSA P, Meani A, Tedone N, Gattuso I, et al
    Gray Matter Damage and Long-Term Disability, Cognitive Outcome, and Survival in Patients With Multiple Sclerosis.
    Neurology. 2026;107:e218310.
    PubMed     Abstract available
    
    
    July 2026
12. GUINEBRETIERE O, Yang F, Wei D, Calonge Q, et al
    Drivers of Rising Prevalence in Major Motor Neurodegenerative Diseases: Temporal Trends in Sweden and France (2003-2022).
    Neurology. 2026;107:e218072.
    PubMed     Abstract available
    
    
    
13. BOS L, Wink AM, Cole JH, Pontillo G, et al
    Mediation Analysis Between Brain Age, Disease-Modifying Factors, and Disability and Cognitive Performance in Multiple Sclerosis.
    Neurology. 2026;107:e218161.
    PubMed     Abstract available
    
    
    
14. TINTORE M, Rovira A
    Redefining Multiple Sclerosis: Toward a Biologically Driven Diagnosis.
    Neurology. 2026;107:e218210.
    PubMed    
    
    
    
15. SCHARF A, Cohen JA, Marrie RA, Miller AE, et al
    Application of the 2024 McDonald Criteria in Individuals With Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study.
    Neurology. 2026;107:e218183.
    PubMed     Abstract available
    
    
    
16. MIRCHI A, Vossough A, Liu GT, Narula S, et al
    Pearls & Oy-sters: Radiologic Lag in Pediatric-Onset Multiple Sclerosis.
    Neurology. 2026;107:e218254.
    PubMed     Abstract available
    
    
    June 2026
17. SHARMIN S, Roos I, Labauge PM, Filippi M, et al
    Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability.
    Neurology. 2026;106:e218056.
    PubMed     Abstract available
    
    
    
18. GOMBOLAY GY, Rubin JP
    Sometimes Kids Really Are Just Little Adults: Early Access to High-Efficacy Therapy Decreases Disability in Pediatric Multiple Sclerosis.
    Neurology. 2026;106:e218168.
    PubMed    
    
    
    
19. KIM W, Watt CL, Fung SG, Yoo S, et al
    Multiple Sclerosis and Outpatient Physician Care in the Last Years of Life: A Population-Based Study.
    Neurology. 2026;106:e218067.
    PubMed     Abstract available
    
    
    May 2026
20. GAVOILLE A, Kerbrat A, Edan G, Le Page E, et al
    Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2026;106:e214943.
    PubMed     Abstract available
    
    
    
21. PLUCHINO S, Mozafari S
    Early Human Intrathecal Mesenchymal Stem Cell Study in Progressive Multiple Sclerosis Faces Delivery Challenges.
    Neurology. 2026;106:e214955.
    PubMed    
    
    
    
22. KVISTAD CE, Krakenes T, Holmoy T, Eidem LE, et al
    Intrathecal Mesenchymal Stem Cells in Progressive Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial (SMART-MS).
    Neurology. 2026;106:e214915.
    PubMed     Abstract available
    
    
    
23. LANGER-GOULD A, Li BH, Smith JB, Nielsen AS, et al
    Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.
    Neurology. 2026;106:e214917.
    PubMed    
    
    
    April 2026
24. TOURNIER A, Gavoille A, Pique J, Levraut M, et al
    Diagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD, and MS.
    Neurology. 2026;106:e214806.
    PubMed     Abstract available
    
    
    
25. BOURDETTE D, Hartung DM
    Industry Payments to Physicians Alter the Care of Patients With Multiple Sclerosis: It's Time to Cut Financial Ties.
    Neurology. 2026;106:e214920.
    PubMed    
    
    
    
26. PATEL AN, Kesselheim AS, Rome BN
    Industry Payments and Prescribing of Brand-Name Multiple Sclerosis Medications in Medicare.
    Neurology. 2026;106:e214834.
    PubMed     Abstract available
    
    
    
27. DE JONG DJ, Schoonheim MM
    The Role of Wearable Devices to Identify Patients at High Risk of Disease Progression in Multiple Sclerosis.
    Neurology. 2026;106:e214742.
    PubMed    
    
    
    
28. FITZGERALD KC, Sanjayan M, Dewey BE, Guha Niyogi P, et al
    Association of Changes in Activity Patterns With Brain Atrophy and Disability Progression in People With Multiple Sclerosis.
    Neurology. 2026;106:e214678.
    PubMed     Abstract available
    
    
    
29. KIM SH, Lee EJ, Lim YM, Kim H, et al
    Prevalence and Relative Proportions of Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the Republic of Korea.
    Neurology. 2026;106:e214792.
    PubMed     Abstract available
    
    
    
30. JACOBS BM, Schalk L, Tregaskis-Daniels E, Scalfari A, et al
    Genetic Determinants of Multiple Sclerosis Susceptibility in People From Diverse Ancestral Backgrounds.
    Neurology. 2026;106:e214708.
    PubMed     Abstract available
    
    
    
31. MARTINEZ SOSA S, Tisavipat N, Betting T, Guo Y, et al
    Pearls & Oy-sters: Using Susceptibility-Based Imaging in Highly Active Late-Onset Multiple Sclerosis.
    Neurology. 2026;106:e214794.
    PubMed     Abstract available
    
    
    
32. LEODORI G, Maccarrone D, Mancuso M, De Bartolo MI, et al
    Resting-State EEG Microstates as Dynamic Biomarkers of Network Dysfunction and Cognitive Impairment in Patients With Multiple Sclerosis.
    Neurology. 2026;106:e214778.
    PubMed     Abstract available
    
    
    
33. DESCHAMPS R, Papeix C, Demortiere S, Lardeux P, et al
    Frequency of AQP4 and MOG Antibodies in Patients With Optic Neuritis Fulfilling Minimal New Multiple Sclerosis MRI Criteria.
    Neurology. 2026;106:e214753.
    PubMed     Abstract available
    
    
    
34. ALFREDSSON L, Johansson E, Olsson T, Stridh P, et al
    Occupational Exposure to Industrial Dust and Rates of Multiple Sclerosis.
    Neurology. 2026;106:e214762.
    PubMed     Abstract available
    
    
    March 2026
35. MILLER AE
    The 2024 McDonald Criteria for Diagnosis of Multiple Sclerosis: The Rubber Meets the Road.
    Neurology. 2026;106:e214688.
    PubMed    
    
    
    
36. BROWNLEE WJ, Maccarrone D, Nistri R, Yam C, et al
    Performance of the 2024 McDonald Criteria in Patients Under Evaluation for Suspected Multiple Sclerosis.
    Neurology. 2026;106:e214688.
    PubMed     Abstract available
    
    
    
37. CHANDRA A, Acharya S, Chandra A
    Global & Community Health: Diagnosis and Management of Multiple Sclerosis in Nepal: Overcoming Barriers Through Local Adaptations.
    Neurology. 2026;106:e214743.
    PubMed     Abstract available
    
    
    
38. VAN NEDERPELT DR, Bos L, Mattiesing RM, Strijbis EM, et al
    Multiple Sclerosis-Specific Reference Curves for Brain Volumes to Explain Disease Severity.
    Neurology. 2026;106:e214694.
    PubMed    
    
    
    February 2026
39. LOCKHART A, Pisa M, Drakesmith H, DeLuca GC, et al
    Iron-Rim Lesions in the Optic Chiasm in Multiple Sclerosis: A Neuropathologic Case Series.
    Neurology. 2026;106:e214515.
    PubMed     Abstract available
    
    
    
40. CAGOL A, Granziera C
    Turning Our Gaze to the Anterior Visual Pathway: Iron Rim Lesions Come Into View in Multiple Sclerosis.
    Neurology. 2026;106:e214590.
    PubMed    
    
    
    January 2026
41. BOS L, Wink AM, Cole JH, Strijbis EMM, et al
    Association of Brain Age With Physical Disability and Cognitive Impairment in People With Multiple Sclerosis of the Same Age.
    Neurology. 2026;106:e214527.
    PubMed     Abstract available
    
    
    
42. LANGER-GOULD A, Li BH, Smith JB, Nielsen AS, et al
    Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.
    Neurology. 2026;106:e214473.
    PubMed     Abstract available
    
    
    
43. MOCCIA M, Silbermann E
    Can Once-Yearly Rituximab Dosing Be "Enough" for Most People With Relapsing Multiple Sclerosis?
    Neurology. 2026;106:e214586.
    PubMed    
    
    
    
44. SPAIN RI, Paz Soldan MM, Freedman MS, Repovic P, et al
    Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.
    Neurology. 2026;106:e214454.
    PubMed     Abstract available
    
    
    
45. BRIGGS FBS, Amezcua L
    Alpha Lipoic Acid in Multiple Sclerosis: It's All in the Details.
    Neurology. 2026;106:e214578.
    PubMed    
    
    
    December 2025
46. DAMULINA A, Opriessnig P, Pirpamer L, Demjaha R, et al
    Association of CSF Kappa-Free Light Chains With Cortical and Periventricular Brain Damage in Multiple Sclerosis.
    Neurology. 2025;105:e214433.
    PubMed     Abstract available
    
    
    
47. TRENTADUE T, Martinez Sosa S, Itoh CY, Modi T, et al
    Clinical Reasoning: A 30-Year-Old Female Patient With Multiple Sclerosis Presenting With Rapidly Progressive Cranial Neuropathies, Weakness, and Ataxia.
    Neurology. 2025;105:e214429.
    PubMed     Abstract available
    
    
    
48. DE MEO E, Addazio I, Portaccio E, Bonacchi R, et al
    Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying Treatments.
    Neurology. 2025;105:e214408.
    PubMed     Abstract available
    
    
    November 2025
49. KRIJNEN EA, Jelgerhuis J, Van Dam M, Bouman PM, et al
    Evolution of Cortical Lesions and Function-Specific Cognitive Decline in People With Multiple Sclerosis.
    Neurology. 2025;105:e214158.
    PubMed    
    
    
    
50. KOZIK V, Dreiling M, Muller D, Tiedge O, et al
    Multiple Sclerosis Relapse Treatment During Pregnancy and Offspring Functional and Structural Neurodevelopment: A Cross-Sectional Study.
    Neurology. 2025;105:e214217.
    PubMed     Abstract available
    
    
    
51. HOGUE O, Zelinsky M, Sonneborn C, Anantasagar T, et al
    Association of Statistical Methodology and Design in Preclinical Animal Studies With Successful Translation Into Clinical Phase 2 Trials.
    Neurology. 2025;105:e214250.
    PubMed     Abstract available
    
    
    
52. PIERRET C, Leray E
    Author Response: Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2025;105:e210260.
    PubMed    
    
    
    
53. GANESH A, Galetta SL
    Editors' Note: Understanding Cancer Risk Among Patients With Multiple Sclerosis.
    Neurology. 2025;105:e214342.
    PubMed    
    
    
    
54. SONG Y, Wang L, Xuan Z
    Reader Response: Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2025;105:e210222.
    PubMed    
    
    
    
55. FENG Q
    Reader Response: Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2025;105:e210223.
    PubMed    
    
    
    October 2025
56. OLIVIERI E, Muller J, Toosy AT
    Predicting Disability Using PIRA in Multiple Sclerosis: Is It as Straightforward as It Appears?
    Neurology. 2025;105:e214206.
    PubMed    
    
    
    
57. PORTACCIO E, Betti M, De Meo E, Pasto L, et al
    Toward a Unified Definition of Progression Independent of Relapse Activity in Multiple Sclerosis.
    Neurology. 2025;105:e213977.
    PubMed     Abstract available
    
    
    
58. O'NEILL KA, Charvet L, Waltz M, George A, et al
    Cognitive Function in People With Pediatric Multiple Sclerosis Over 2 Years.
    Neurology. 2025;105:e214142.
    PubMed     Abstract available
    
    
    
59. PORTACCIO E, Amato MP
    Moving Closer to the Prevention of Cognitive Disability in People With Pediatric-Onset Multiple Sclerosis.
    Neurology. 2025;105:e214244.
    PubMed    
    
    
    
60. SAHI N, Ciccarelli O, Houlden H, Chard DT, et al
    Unlocking Multiple Sclerosis Genetics: From Susceptibility to Severity.
    Neurology. 2025;105:e214141.
    PubMed     Abstract available
    
    
    
61. BSTEH G, Hegen H, Krajnc N, Fottinger F, et al
    Association Between Retinal Layer Atrophy With Clinical and Radiologic Progression in People With Relapsing Multiple Sclerosis.
    Neurology. 2025;105:e214069.
    PubMed     Abstract available
    
    
    September 2025
62. CORTESE R, Sforazzini F, Gentile G, de Mauro A, et al
    Deep Learning Modeling to Differentiate Multiple Sclerosis From MOG Antibody-Associated Disease.
    Neurology. 2025;105:e214075.
    PubMed     Abstract available
    
    
    
63. CHARD DT
    Diagnosing Multiple Sclerosis: An Imperfect but Evolving Process.
    Neurology. 2025;105:e214057.
    PubMed    
    
    
    
64. RENNER B, Verter ED, Absinta M, Daboul L, et al
    Frequency and Diagnostic Implications of Paramagnetic Rim Lesions in People Presenting for Diagnosis to a Multiple Sclerosis Clinic.
    Neurology. 2025;105:e213912.
    PubMed     Abstract available
    
    
    August 2025
65. GAVOILLE A, Leray E, Marignier R, Rollot F, et al
    Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis.
    Neurology. 2025;105:e213907.
    PubMed     Abstract available
    
    
    
66. BSTEH G, Hegen H
    Bridging the Sex Gap: Confronting Therapeutic Inertia in Women With Multiple Sclerosis.
    Neurology. 2025;105:e214073.
    PubMed    
    
    
    
67. AL-ARAJI S, Moccia M, Jha A, Zhang L, et al
    Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2025;105:e213967.
    PubMed     Abstract available
    
    
    
68. NEWSOME SD, Krzystanek E, Selmaj KW, Dufek M, et al
    Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.
    Neurology. 2025;105:e213909.
    PubMed    
    
    
    
69. CORTESE M, Peng X, Edan G, Freedman MS, et al
    Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression.
    Neurology. 2025;105:e213905.
    PubMed     Abstract available
    
    
    
70. BOURDETTE D, Wooliscroft L
    Late-Onset Multiple Sclerosis: Is Disease-Modifying Therapy Indicated?
    Neurology. 2025;105:e213971.
    PubMed    
    
    
    
71. ROBIN C, Rollot F, Lefort M, Casey R, et al
    Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple Sclerosis.
    Neurology. 2025;105:e213744.
    PubMed     Abstract available
    
    
    July 2025
72. JIA A, Price TR, Rosner J, Broderick C, et al
    Journal Club: Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2025;105:e213663.
    PubMed     Abstract available
    
    
    June 2025
73. GOYNE C, Fair AE, Yilmaz D, Race J, et al
    Epigenetic Aging in Pediatric-Onset Multiple Sclerosis.
    Neurology. 2025;104:e213673.
    PubMed     Abstract available
    
    
    
74. YEH EA
    Accelerated Aging in Children With Multiple Sclerosis: Can We Stop the Clock?
    Neurology. 2025;104:e213840.
    PubMed    
    
    
    
75. KRIJNEN EA, Jelgerhuis J, Van Dam M, Bouman PM, et al
    Evolution of Cortical Lesions and Function-Specific Cognitive Decline in People With Multiple Sclerosis.
    Neurology. 2025;104:e213650.
    PubMed     Abstract available
    
    
    May 2025
76. VAN NEDERPELT DR, Bos L, Mattiesing RM, Strijbis EMM, et al
    Multiple Sclerosis-Specific Reference Curves for Brain Volumes to Explain Disease Severity.
    Neurology. 2025;104:e213618.
    PubMed     Abstract available
    
    
    
77. FOX RJ, Rudick RA
    A Newly Validated Gold Standard for Measuring Multiple Sclerosis Disability Worsening.
    Neurology. 2025;104:e213672.
    PubMed    
    
    
    
78. LANGER-GOULD A, Li BH, Smith JB, Kanter MH, et al
    Racial Inequities, Multiple Sclerosis, and Implementation of a Novel Treatment Algorithm at the Health System Level.
    Neurology. 2025;104:e213607.
    PubMed     Abstract available
    
    
    
79. KAPPOS L, Yiu S, Dahlke F, Coetzee T, et al
    Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials.
    Neurology. 2025;104:e213558.
    PubMed     Abstract available
    
    
    
80. CHAGGAR G, Waldner D, Scozzafava J, Harrison R, et al
    Teaching NeuroImage: Severe Enterovirus Encephalitis as a Complication of Ocrelizumab Treatment for Multiple Sclerosis.
    Neurology. 2025;104:e213585.
    PubMed    
    
    
    
81. MARRIE RA, Sharma M, Cutter GR, Fox RJ, et al
    Perspectives of People With Multiple Sclerosis Regarding Data Linkage and Sharing.
    Neurology. 2025;104:e213587.
    PubMed     Abstract available
    
    
    
82. NEWSOME SD, Krzystanek E, Selmaj KW, Dufek M, et al
    Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.
    Neurology. 2025;104:e213574.
    PubMed     Abstract available
    
    
    
83. GUINEBRETIERE O, Pierret C, Calonge Q, Januel E, et al
    Updated Multiple Sclerosis Incidence in France, 2011-2021.
    Neurology. 2025;104:e213586.
    PubMed     Abstract available
    
    
    April 2025
84. GANESH A, Galetta SL
    Editors' Note: Domestic Violence and Abuse in People Living With Multiple Sclerosis.
    Neurology. 2025;104:e213407.
    PubMed    
    
    
    
85. BROWNLEE WJ, Foster MA, Pontillo G, Davagnanam I, et al
    Investigating Whether Dissemination in Time Is Essential to Diagnose Relapsing Multiple Sclerosis.
    Neurology. 2025;104:e210274.
    PubMed     Abstract available
    
    
    
86. VIDAL-JORDANA A, Ontaneda D
    To Kill Time: A Bold Step Toward Simplifying Multiple Sclerosis Diagnosis.
    Neurology. 2025;104:e213416.
    PubMed    
    
    
    
87. MAHAJAN KR, Herman D, Zheng Y, Androjna C, et al
    Neurodegeneration and Demyelination in the Multiple Sclerosis Spinal Cord: Clinical, Pathological, and 7T MRI Perspectives.
    Neurology. 2025;104:e210259.
    PubMed     Abstract available
    
    
    March 2025
88. GOMEZ-FIGUEROA E, Moreno-Bernardino CJ, De Alba-Sanchez AM, Guerrero-Udave N, et al
    The Burden of Multiple Sclerosis in Mexico.
    Neurology. 2025;104:e213343.
    PubMed     Abstract available
    
    
    February 2025
89. TRANFA M, Petracca M, Moccia M, Scaravilli A, et al
    Conventional MRI-Based Structural Disconnection and Morphometric Similarity Networks and Their Clinical Correlates in Multiple Sclerosis.
    Neurology. 2025;104:e213349.
    PubMed     Abstract available
    
    
    
90. MARRIE RA, Bolton J, Ling YV, Bernstein C, et al
    Peripartum Mental Illness in Mothers With Multiple Sclerosis and Other Chronic Diseases in Ontario, Canada.
    Neurology. 2025;104:e210170.
    PubMed     Abstract available
    
    
    
91. ROSS LA
    Peripartum Mental Illness in Mothers With Multiple Sclerosis Merits Neurologists' Attention.
    Neurology. 2025;104:e213366.
    PubMed    
    
    
    
92. DERSCH RS, Fingerle V, Berns J, Rauer S, et al
    Pearls & Oy-sters: Recurrent Lyme Neuroborreliosis With Seroreversion in a Patient With Multiple Sclerosis on a B-Cell Depleting Therapy.
    Neurology. 2025;104:e213330.
    PubMed     Abstract available
    
    
    
93. CERQUEIRA JJ, Berthele A, Cree BAC, Filippi M, et al
    Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension.
    Neurology. 2025;104:e210142.
    PubMed     Abstract available
    
    
    
94. ROCCA MA, Preziosa P, Filippi M
    Age Matters in Multiple Sclerosis: Novel Insights Into Disease Progression From Clinical Onset.
    Neurology. 2025;104:e213396.
    PubMed    
    
    
    
95. COBO-CALVO A, Carbonell-Mirabent P, Tur C, Otero-Romero S, et al
    Age-Related Disability Outcomes After a First Demyelinating Event.
    Neurology. 2025;104:e210305.
    PubMed     Abstract available
    
    
    
96. BRENTON JN
    Menarche and Relapses in Multiple Sclerosis: Associations Between a Physiologic Developmental Milestone and Disease Activity.
    Neurology. 2025;104:e213321.
    PubMed    
    
    
    
97. KRYSKO KM, Waltz M, Chitnis T, Weinstock-Guttman B, et al
    Study of the Association Between Menarche and Disease Course in Pediatric Multiple Sclerosis.
    Neurology. 2025;104:e210213.
    PubMed     Abstract available
    
    
    
98. BALCOM EF, Mccombe JA, Kate MP, Vu K, et al
    Inequities in the Use of Disease-Modifying Therapy Among Adults Living With Multiple Sclerosis in Urban and Rural Areas in Alberta, Canada.
    Neurology. 2025;104:e210251.
    PubMed     Abstract available
    
    
    
99. CARVAJAL R, Guananga-Alvarez D, Tur C, Esperalba J, et al
    Effect of the Number of Vaccine Doses Before Starting Anti-CD20 Therapy on Seroprotection Rates Against Hepatitis B Virus in People With MS.
    Neurology. 2025;104:e210281.
    PubMed     Abstract available
    
    
    
100. AMEZCUA L, Cardenas-Iniguez C, Orlando C, Martinez A, et al
     Person-Centered Social Determinants and Neighborhood-Level Deprivation Associated With Disability in Hispanic People With Multiple Sclerosis.
     Neurology. 2025;104:e213332.
     PubMed     Abstract available
     
     
     January 2025
101. TSAI CC, Chen J, Pikula A, Johnson EL, et al
     Opinion & Special Articles: Beyond Pronouns-Educating Trainees on the Impact of Language on Gender Inclusivity in Neurologic Practice.
     Neurology. 2025;104:e210289.
     PubMed     Abstract available
     
     
     
102. CAGOL A, Montobbio N
     Reassuring Insights Into the Effect of COVID-19 on Symptoms and Disability in People With Multiple Sclerosis: Weathering the Storm.
     Neurology. 2025;104:e210272.
     PubMed    
     
     
     
103. SILVERMAN HE, Bostrom A, Nylander AN, Akula A, et al
     Association of Menopause With Functional Outcomes and Disease Biomarkers in Women With Multiple Sclerosis.
     Neurology. 2025;104:e210228.
     PubMed     Abstract available
     
     
     
104. SALTER A, Lancia S, Cutter GR, Fox RJ, et al
     Effects of COVID-19 Infection on Symptom Severity and Disability in Multiple Sclerosis.
     Neurology. 2025;104:e210149.
     PubMed     Abstract available
     
     
     
105. CRUCIANI A, Toosy AT
     Progression Independent of Relapse Activity in Multiple Sclerosis: More, or Less, Than Meets the Eye?
     Neurology. 2025;104:e210296.
     PubMed    
     
     
     
106. STRIJBIS EMM, Mostert J, Comtois J, Salter A, et al
     Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple Sclerosis.
     Neurology. 2025;104:e210153.
     PubMed     Abstract available
     
     
     
107. MONGAY-OCHOA N, Pareto D, Alberich M, Carbonell-Mirabent P, et al
     Association of the Cervical Canal Area With Disability and Progression in People With Multiple Sclerosis.
     Neurology. 2025;104:e210136.
     PubMed     Abstract available
     
     
     December 2024
108. RIMKUS CM, Nucci MP, Avolio IB, Apostolos-Pereira SL, et al
     Atrophy Patterns in Patients With Multiple Sclerosis With Cognitive Impairment, Fatigue, and Mood Disorders.
     Neurology. 2024;103:e210080.
     PubMed     Abstract available
     
     
     
109. ROSS R, O'Neill KA, Betensky RA, Billiet T, et al
     Association of Social Determinants of Health With Brain MRI Outcomes in Individuals With Pediatric Onset Multiple Sclerosis.
     Neurology. 2024;103:e210140.
     PubMed     Abstract available
     
     
     
110. HARTUNG HP, Benedict RHB, Berger T, Bermel RA, et al
     Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.
     Neurology. 2024;103:e210049.
     PubMed     Abstract available
     
     
     
111. QUINN CM, Rajarajan P, Gill AJ, Kopinsky H, et al
     Neurologic Outcomes in People With Multiple Sclerosis Treated With Immune Checkpoint Inhibitors for Oncologic Indications.
     Neurology. 2024;103:e210003.
     PubMed     Abstract available
     
     
     
112. WILSON E, Meeks HD, Barney BJ, Waltz M, et al
     Epidemiology and Impact of Social Hardships in Children With Multiple Sclerosis in the United States.
     Neurology. 2024;103:e209991.
     PubMed     Abstract available
     
     
     November 2024
113. REEVES JA, Bartnik A, Jakimovski D, Mohebbi M, et al
     Associations Between Paramagnetic Rim Lesion Evolution and Clinical and Radiologic Disease Progression in Persons With Multiple Sclerosis.
     Neurology. 2024;103:e210004.
     PubMed     Abstract available
     
     
     
114. WATANABE M, Isobe N, Niino M, Nakashima I, et al
     Prevalence of, and Disability Due to, Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in Japan by the Fifth Nationwide Survey.
     Neurology. 2024;103:e209992.
     PubMed     Abstract available
     
     
     
115. GUSOVSKY AV, Lin CC, Kerber K, Reynolds EL, et al
     Costs Are Still on the Rise for Commonly Prescribed Branded Neurologic Medications.
     Neurology. 2024;103:e210029.
     PubMed     Abstract available
     
     
     
116. MICHAELSON NM, Klawiter EC, Singhal T
     Journal Club: PET Imaging in Multiple Sclerosis and Its Prognostic Implications.
     Neurology. 2024;103:e210047.
     PubMed    
     
     
     
117. PONTILLO G, Prados F, Colman J, Kanber B, et al
     Disentangling Neurodegeneration From Aging in Multiple Sclerosis Using Deep Learning: The Brain-Predicted Disease Duration Gap.
     Neurology. 2024;103:e209976.
     PubMed     Abstract available
     
     
     
118. BROEDERS TAA, van Dam M, Pontillo G, Rauh V, et al
     Energy Associated With Dynamic Network Changes in Patients With Multiple Sclerosis and Cognitive Impairment.
     Neurology. 2024;103:e209952.
     PubMed     Abstract available
     
     
     
119. PIERRET C, Mulliez A, Le Bihan-Benjamin C, Moisset X, et al
     Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
     Neurology. 2024;103:e209885.
     PubMed     Abstract available
     
     
     October 2024
120. SIEGLER JE 3RD, Galetta S
     Editors' Note: Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
     Neurology. 2024;103:e209893.
     PubMed    
     
     
     
121. GROBOIS L, You M, Etienne M
     Reader Response: Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
     Neurology. 2024;103:e209508.
     PubMed    
     
     
     
122. SALTER A, Lancia S, Kowalec K, Fitzgerald KC, et al
     Author Response: Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
     Neurology. 2024;103:e209515.
     PubMed    
     
     
     
123. HAY M, Rollot F, Casey R, Kerbrat A, et al
     Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life Study.
     Neurology. 2024;103:e209886.
     PubMed     Abstract available
     
     
     
124. YOKOTE H, Mori K, Nakamichi K, Matsuda T, et al
     Global Hyperperfusion in the Brain at Onset of the Immune Reconstitution Inflammatory Syndrome in a Patient With Natalizumab-Associated PML.
     Neurology. 2024;103:e209874.
     PubMed    
     
     
     
125. 
     Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
     Neurology. 2024;103:e209461.
     PubMed    
     
     
     
126. 
     Patient and Physician Perspectives on the Wearing-Off Effect in Multiple Sclerosis: Results From Structured Interviews (P1-6.015).
     Neurology. 2024;103:e209905.
     PubMed    
     
     
     
127. LOONSTRA FC, Alvarez Sirvent D, Tesi N, Holstege H, et al
     Association of Polygenic Risk Score With Lifetime Risk of Developing Multiple Sclerosis in a Population-Based Birth-Year Cohort.
     Neurology. 2024;103:e209663.
     PubMed     Abstract available
     
     
     September 2024
128. ROVIRA A, Pareto D
     chi-Separation as a Novel MRI Biomarker for Assessing Disease Progression in Multiple Sclerosis: Divide and Conquer.
     Neurology. 2024;103:e209735.
     PubMed    
     
     
     
129. MULLER J, Lu PJ, Cagol A, Ruberte E, et al
     Quantifying Remyelination Using chi-Separation in White Matter and Cortical Multiple Sclerosis Lesions.
     Neurology. 2024;103:e209604.
     PubMed     Abstract available
     
     
     
130. BOURDETTE D
     Investigating When Patients With Multiple Sclerosis Should Switch From a Low- or Moderate-Efficacy Therapy to a High-Efficacy Treatment.
     Neurology. 2024;103:e209835.
     PubMed    
     
     
     
131. BSTEH G, Aicher ML, Walde JF, Krajnc N, et al
     Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI Activity.
     Neurology. 2024;103:e209752.
     PubMed     Abstract available
     
     
     
132. BANKS SA, Brinjikji W, Giannini C, Syc-Mazurek SB, et al
     Intra-arterial Melphalan as Targeted Therapy for Tumefactive Multiple Sclerosis Lesions.
     Neurology. 2024;103:e209739.
     PubMed    
     
     
     
133. ABBOUD H, Farez MF
     The Risk of Multiple Sclerosis Relapse After Vaccination: Can a Population-Based Study of Mass Vaccination End the Longstanding Debate?
     Neurology. 2024;103:e209761.
     PubMed    
     
     
     
134. MOISSET X, Leray E, Chenaf C, Taithe F, et al
     Risk of Relapse After COVID-19 Vaccination Among Patients With Multiple Sclerosis in France: A Self-Controlled Case Series.
     Neurology. 2024;103:e209662.
     PubMed     Abstract available
     
     
     August 2024
135. KARALIUS M, Mohan S, Paredes D, Rasool N, et al
     Pearls & Oy-sters: Optic Neuritis as First Demyelinating Event During Pregnancy in 2 Young Hispanic Women: MS vs MOGAD.
     Neurology. 2024;103:e209706.
     PubMed     Abstract available
     
     
     
136. SASTRE-GARRIGA J, Vidal-Jordana A, Toosy AT, Enzinger C, et al
     Value of Optic Nerve MRI in Multiple Sclerosis Clinical Management: A MAGNIMS Position Paper and Future Perspectives.
     Neurology. 2024;103:e209677.
     PubMed     Abstract available
     
     
     
137. WILLIAMS MJ, Amezcua L, Cohan SL, Cohen JA, et al
     Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses.
     Neurology. 2024;103:e209610.
     PubMed     Abstract available
     
     
     July 2024
138. PFEUFFER S, Wolff S, Aslan D, Rolfes L, et al
     Association of Clinical Relapses With Disease Outcomes in Multiple Sclerosis Patients Older Than 50 Years.
     Neurology. 2024;103:e209574.
     PubMed     Abstract available
     
     
     
139. CICCARELLI O, Barkhof F, Calabrese M, De Stefano N, et al
     Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis.
     Neurology. 2024;103:e209444.
     PubMed     Abstract available
     
     
     
140. MADSEN MA, Povazan M, Wiggermann V, Lundell H, et al
     Association of Cortical Lesions With Regional Glutamate, GABA, N-Acetylaspartate, and Myoinositol Levels in Patients With Multiple Sclerosis.
     Neurology. 2024;103:e209543.
     PubMed     Abstract available
     
     
     June 2024
141. PALLADINO R, Monasta L
     Estimating the Prevalence and Burden of Multiple Sclerosis in China Using the Global Burden of Disease Study: Challenges and Future Directions.
     Neurology. 2024;102:e209521.
     PubMed    
     
     
     
142. ZHANG C, Liu W, Wang L, Wang F, et al
     Prevalence and Burden of Multiple Sclerosis in China, 1990-2019: Findings From the Global Burden of Disease Study 2019.
     Neurology. 2024;102:e209351.
     PubMed     Abstract available
     
     
     May 2024
143. CACCIAGUERRA L, Abdel-Mannan O, Champsas D, Mankad K, et al
     Radiologic Lag and Brain MRI Lesion Dynamics During Attacks in MOG Antibody-Associated Disease.
     Neurology. 2024;102:e209303.
     PubMed     Abstract available
     
     
     
144. SILBERMANN E, Spain RI
     Serum Neurofilament Light Chain for Multiple Sclerosis Relapses: Too Little Too Late?
     Neurology. 2024;102:e209456.
     PubMed    
     
     
     
145. FOX RJ, Cree BAC, de Seze J, Gold R, et al
     Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
     Neurology. 2024;102:e209357.
     PubMed     Abstract available
     
     
     
146. MICHAELSON NM
     Right Brain: The Unraveling.
     Neurology. 2024;102:e209492.
     PubMed     Abstract available
     
     
     
147. VYAS MV, Kapral MK, Alonzo R, Fang J, et al
     Proportion of Life Spent in Canada and the Incidence of Multiple Sclerosis in Permanent Immigrants.
     Neurology. 2024;102:e209350.
     PubMed     Abstract available
     
     
     April 2024
148. 
     Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria: A Longitudinal, Prospective, Multicenter Study.
     Neurology. 2024;102:e209214.
     PubMed    
     
     
     
149. OLIVE-CIRERA G, Bruijstens AL, Fonseca EG, Chen LW, et al
     MOG Antibodies Restricted to CSF in Children With Inflammatory CNS Disorders.
     Neurology. 2024;102:e209199.
     PubMed     Abstract available
     
     
     
150. SPELMAN T, Simoneau G, Hyde R, Kuhelj R, et al
     Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study.
     Neurology. 2024;102:e208114.
     PubMed     Abstract available
     
     
     
151. YU Y, Kushlaf H
     Multiple Sclerosis in a Patient with Friedreich's Ataxia (P4-6.016).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
152. WATANABE F, Fedorko J, Imitola J
     Dimethyl Fumarate Enhances Neural Stem Cell (NSC) Self-renewal and Neuroprotection in a Human Cellular Model of Multiple Sclerosis Inflammation-induced Neurodegeneration (P8-6.014).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
153. LOBAINA M, Valaparla VL, Shanina E
     Vogt-Koyanagi-Harada Disease an Autoimmune Comorbidity of Multiple Sclerosis, Not Just a Mimicker (P3-14.014).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
154. KARAYI G, Quinones-Herrero N, Martin J, Chaudhry S, et al
     A Retrospective Analysis of Disease Modifying Drug Discontinuation in Patients with Multiple Sclerosis (S31.010).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
155. ROSE M, Hsu S, Balan A, Anderson A, et al
     Risk Factors for Peripartum Mood Disorders in Women with MS: A Prospective Study (P4-6.014).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
156. WOODSON S, Gettings E, Guo CY, Klineova S, et al
     Real-world Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates (P4-6.005).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
157. MIKAMI T, Levy M
     Association of HLA-DRB1*15:01 Status with Transcriptomic Pattern of B cells in CSF in Multiple Sclerosis (P7-6.011).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     March 2024
158. MARRIE RA, Salter A
     Off-Road Testing: Outcome Reporting Bias in Multiple Sclerosis Trials.
     Neurology. 2024;102:e208099.
     PubMed    
     
     
     
159. LEMMENS CMC, van Amerongen S, Strijbis EM, Killestein J, et al
     Outcome Reporting Bias in Clinical Trials Researching Disease-Modifying Therapy in Patients With Multiple Sclerosis.
     Neurology. 2024;102:e208032.
     PubMed     Abstract available
     
     
     
160. 
     Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
     Neurology. 2024;102:e209252.
     PubMed    
     
     
     
161. BOURDETTE D, Wooliscroft L
     The Challenges of Treating Late-Onset Multiple Sclerosis.
     Neurology. 2024;102:e209146.
     PubMed    
     
     
     
162. MOURESAN EF, Mentesidou E, Berglund A, Mckay KA, et al
     Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
     Neurology. 2024;102:e208051.
     PubMed     Abstract available
     
     
     
163. SALTER A, Lancia S, Kowalec K, Fitzgerald KC, et al
     Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
     Neurology. 2024;102:e209135.
     PubMed     Abstract available
     
     
     
164. CHARD DT
     Chronically Active Lesions as a Trial Outcome in Multiple Sclerosis: A New Perspective on an Old Foe.
     Neurology. 2024;102:e209246.
     PubMed    
     
     
     
165. ARNOLD DL, Elliott C, Martin EC, Hyvert Y, et al
     Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.
     Neurology. 2024;102:e208058.
     PubMed     Abstract available
     
     
     
166. PAPP V, Magyari M, Moller S, Sellebjerg F, et al
     Mortality of the Danish Nationwide AQP4 Antibody-Seropositive Neuromyelitis Optica Spectrum Disorder Patient Cohort.
     Neurology. 2024;102:e209147.
     PubMed     Abstract available
     
     
     February 2024
167. RADZIK AM, Amezcua L, Anderson A, Gilmore S, et al
     Disparities by Race in Pregnancy Care and Clinical Outcomes in Women With Multiple Sclerosis: A Diverse Multicenter Cohort.
     Neurology. 2024;102:e208100.
     PubMed     Abstract available
     
     
     
168. GALBUSERA R, Bahn E, Weigel M, Cagol A, et al
     Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
     Neurology. 2024;102:e207966.
     PubMed     Abstract available
     
     
     
169. NG HS, Zhu F, Zhao Y, Yao S, et al
     Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis.
     Neurology. 2024;102:e208006.
     PubMed     Abstract available
     
     
     
170. BRIDGE F, Brotherton J, Stankovich J, Sanfilippo PG, et al
     Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies.
     Neurology. 2024;102:e208059.
     PubMed     Abstract available
     
     
     January 2024
171. GIBSON S, Mcgraw C
     Teaching NeuroImage: Cryptococcus in a Woman With Multiple Sclerosis on Fingolimod.
     Neurology. 2024;102:e208027.
     PubMed     Abstract available
     
     
     
172. MCGINLEY MP, Harvey T, Lopez R, Ontaneda D, et al
     Geographic Disparities in Access to Neurologists and Multiple Sclerosis Care in the United States.
     Neurology. 2024;102:e207916.
     PubMed     Abstract available
     
     
     
173. LANGER-GOULD A, Sotirchos ES, Bourdette D
     Rituximab for Multiple Sclerosis.
     Neurology. 2024;102:e208063.
     PubMed     Abstract available
     
     
     
174. GALETTA S, Brownlee W
     Assignment Completed.
     Neurology. 2024;102:e207913.
     PubMed     Abstract available
     
     
     
175. TUR C, Rocca MA
     Progression Independent of Relapse Activity in Multiple Sclerosis.
     Neurology. 2024;102:e207936.
     PubMed     Abstract available
     
     
     
176. VIDAL-JORDANA A, Rovira A, Calderon W, Arrambide G, et al
     Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria.
     Neurology. 2024;102:e200805.
     PubMed     Abstract available
     
     
     
177. CAGOL A, Benkert P, Melie-Garcia L, Schaedelin SA, et al
     Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS.
     Neurology. 2024;102:e207768.
     PubMed     Abstract available
     
     
     December 2023
178. ROLLOT F, Uhry Z, Dantony E, Vukusic S, et al
     Comparison of 2 Methods for Estimating Multiple Sclerosis-Related Mortality.
     Neurology. 2023;101:e2483-e2496.
     PubMed     Abstract available
     
     
     
179. GUINEBRETIERE O, Nedelec T, Gantzer L, Lekens BB, et al
     Association Between Diseases and Symptoms Diagnosed in Primary Care and the Subsequent Specific Risk of Multiple Sclerosis.
     Neurology. 2023 Dec 5:10.1212/WNL.0000000000207981.
     PubMed     Abstract available
     
     
     October 2023
180. SOTIRCHOS ES, Hu C, Smith MD, Lord HN, et al
     Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis.
     Neurology. 2023 Oct 10:10.1212/WNL.0000000000207957.
     PubMed     Abstract available
     
     
     September 2023
181. COBO-CALVO A, Tur C, Otero-Romero S, Carbonell-Mirabent P, et al
     Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating Event.
     Neurology. 2023;101:e1280-e1292.
     PubMed     Abstract available
     
     
     
182. PALLADINO R, Strijbis EM
     How Far Are We in Translating the Multiple Sclerosis Prodromes in Clinical Practice?
     Neurology. 2023 Sep 25:10.1212/WNL.0000000000207989.
     PubMed    
     
     
     
183. CHERTCOFF AS, Yusuf F, Zhu F, Evans C, et al
     Psychiatric Comorbidity During the Prodromal Period in Patients With Multiple Sclerosis.
     Neurology. 2023 Sep 25:10.1212/WNL.0000000000207843.
     PubMed     Abstract available
     
     
     
184. HUPPKE BM, Reinert M, Hummel-Abmeier H, Stark W, et al
     Pretreatment Neurofilament Light Chain Serum Levels, Early Disease Severity, and Treatment Response in Pediatric Multiple Sclerosis.
     Neurology. 2023 Sep 25:10.1212/WNL.0000000000207791.
     PubMed     Abstract available
     
     
     
185. ALMRAMHI MM, Finan C, Storm CS, Schmidt AF, et al
     Exploring the Role of Plasma Lipids and Statins Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study.
     Neurology. 2023 Sep 1:10.1212/WNL.0000000000207777.
     PubMed     Abstract available
     
     
     
186. BUYUKKURT A, Harroud A
     The Potential to Inform Statin Use in Multiple Sclerosis Through Human Genetics [re: WNL-2023-000524].
     Neurology. 2023 Sep 1:10.1212/WNL.0000000000207773.
     PubMed    
     
     
     August 2023
187. BSTEH G, Hegen H, Altmann P, Auer M, et al
     Diagnostic Performance of Adding the Optic Nerve Region Assessed by Optical Coherence Tomography to the Diagnostic Criteria for Multiple Sclerosis.
     Neurology. 2023;101:e784-e793.
     PubMed     Abstract available
     
     
     
188. GRAVES JS
     Cell Specific Aging in Multiple Sclerosis.
     Neurology. 2023 Aug 4:10.1212/WNL.0000000000207679.
     PubMed    
     
     
     
189. MALTBY V, Xavier A, Ewing E, Campagna MP, et al
     Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis.
     Neurology. 2023 Aug 4:10.1212/WNL.0000000000207489.
     PubMed     Abstract available
     
     
     July 2023
190. FADDA G, Cardenas de la Parra A, O'Mahony J, Waters P, et al
     Deviation From Normative Whole Brain and Deep Gray Matter Growth in Children With MOGAD, MS, and Monophasic Seronegative Demyelination.
     Neurology. 2023;101:e425-e437.
     PubMed     Abstract available
     
     
     
191. COUSTAL C, Goulabchand R, Labauge P, Guilpain P, et al
     Clinical, Radiologic, and Immunologic Features of Patients With CTLA4 Deficiency With Neurologic Involvement.
     Neurology. 2023 Jul 24:10.1212/WNL.0000000000207609.
     PubMed     Abstract available
     
     
     
192. SCHWEITZER F, Laurent S, Cortese I, Fink GR, et al
     Progressive Multifocal Leukoencephalopathy: Pathogenesis, Diagnostic Tools, and Potential Biomarkers of Response to Therapy.
     Neurology. 2023 Jul 24:10.1212/WNL.0000000000207622.
     PubMed     Abstract available
     
     
     
193. LONGBRAKE E, Kalincik T
     Early Treatment for Multiple Sclerosis: Time Is Brain.
     Neurology. 2023 Jul 19:10.1212/WNL.0000000000207754.
     PubMed    
     
     
     
194. EHRHARDT H, Lambe J, Moussa H, Vasileiou ES, et al
     Effects of Ibudilast on Retinal Atrophy in Progressive Multiple Sclerosis Subtypes: Post-Hoc Analyses of the SPRINT-MS Trial.
     Neurology. 2023 Jul 17:10.1212/WNL.0000000000207551.
     PubMed     Abstract available
     
     
     
195. BENNETT JL
     Sprinting to the Finish: Optical Coherence Tomography, Retinal Atrophy, and Neurodegeneration in Progressive Multiple Sclerosis.
     Neurology. 2023 Jul 17:10.1212/WNL.0000000000207607.
     PubMed    
     
     
     
196. JAIN A, Arena VP, Steigerwald C, Borja MJ, et al
     Pearls and Oy-sters: CSF1R-Related Leukoencephalopathy With Spinal Cord Lesions Mimicking Multiple Sclerosis.
     Neurology. 2023 Jul 5:10.1212/WNL.0000000000207502.
     PubMed     Abstract available
     
     
     
197. TOOSY AT, Vidal-Jordana A
     Is the Optic Nerve Overdue as a Criterion to Support the Diagnosis of Multiple Sclerosis?
     Neurology. 2023 Jul 3:10.1212/WNL.0000000000207625.
     PubMed    
     
     
     June 2023
198. KOCH-HENRIKSEN N
     Worldwide Disparity in the Effectiveness of the Diagnostic Process in Multiple Sclerosis.
     Neurology. 2023 Jun 30:10.1212/WNL.0000000000207530.
     PubMed    
     
     
     
199. SOLOMON AJ, Marrie RA, Viswanathan S, Correale J, et al
     Global Barriers to the Diagnosis of Multiple Sclerosis: Data From the Multiple Sclerosis International Federation Atlas of MS, Third Edition.
     Neurology. 2023 Jun 15:10.1212/WNL.0000000000207481.
     PubMed     Abstract available
     
     
     
200. ROTSTEIN D, Schneider R
     A Birth Year Cohort and What It Can Reveal About Lipid Mediators as Putative Biomarkers of Progression in Multiple Sclerosis.
     Neurology. 2023 Jun 8:10.1212/WNL.0000000000207605.
     PubMed    
     
     
     
201. BROOS JY, Loonstra FC, de Ruiter LRJ, Gouda MMTEE, et al
     Association of Arachidonic Acid-Derived Lipid Mediators With Disease Severity in Patients With Relapsing and Progressive Multiple Sclerosis.
     Neurology. 2023 Jun 8:10.1212/WNL.0000000000207459.
     PubMed     Abstract available
     
     
     
202. KOWALEC K, Fitzgerald KC, Salter A, Dolovich C, et al
     Polygenicity of Comorbid Depression in Multiple Sclerosis.
     Neurology. 2023 Jun 8:10.1212/WNL.0000000000207457.
     PubMed     Abstract available
     
     
     April 2023
203. LUSK JB, Hoffman MN, Clark AG, Bae J, et al
     Association Between Neighborhood Socioeconomic Status and 30-Day Mortality and Readmission for Patients With Common Neurologic Conditions.
     Neurology. 2023;100:e1776-e1786.
     PubMed     Abstract available
     
     
     
204. LEAVITT VM
     The Mismeasure of Change: Better Cognitive Measurement Instruments are Urgently Needed for Multiple Sclerosis Research.
     Neurology. 2023 Apr 18:10.1212/WNL.0000000000207431.
     PubMed    
     
     
     
205. CASTROGIOVANNI N, Mostert J, Repovic P, Bowen JD, et al
     Longitudinal Changes in Cognitive Test Scores in Patients With Relapsing Remitting Multiple Sclerosis: An Analysis of the DECIDE Dataset.
     Neurology. 2023 Apr 18:10.1212/WNL.0000000000207301.
     PubMed     Abstract available
     
     
     March 2023
206. CARTA S, Cobo Calvo A, Armangue T, Saiz A, et al
     Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study.
     Neurology. 2023;100:e1095-e1108.
     PubMed     Abstract available
     
     
     September 2022
207. B SYC-MAZUREK S, Chen JJ, Morris P, Sechi E, et al
     Frequency of New or Enlarging Lesions on MRI Outside of Clinical Attacks in Patients With MOG-Antibody-Associated Disease.
     Neurology. 2022 Sep 29. pii: WNL.0000000000201263.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum